Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TPB files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Departure of CEO (new) — The CEO is leaving the company, which is a material leadership change.
Turning Point Brands CEO Graham Purdy resigns; Executive Chairman David Glazek named CEO
Filed September 21, 2026 · Period ending September 18, 2026 · ~1 min read
Key Changes
-
high
CEO Graham Purdy resigned as President, CEO, and board member for personal reasons, effective September 30, 2026.
Item 5.02 verify on EDGAR → -
high
Executive Chairman David Glazek, a director since 2012, was appointed CEO effective October 1, 2026.
Item 5.02 verify on EDGAR → -
high
The company tightened full-year 2026 EBITDA guidance to $70–$80 million from $70–$90 million, citing no onshoring margin benefit until 2027 and prolonged higher freight costs.
Exhibit 99.1 view on EDGAR → -
medium
Full-year 2026 Modern Oral gross sales guidance of $330–$350 million and net sales guidance of $260–$270 million were reaffirmed.
Exhibit 99.1 view on EDGAR →
Summary
Turning Point Brands announced that CEO Graham Purdy has resigned for personal reasons, effective September 30, 2026. The company stated the departure was not related to any disagreement with the company or its board. Executive Chairman David Glazek, who has been a director since 2012, will take over as CEO on October 1, 2026.
The leadership change comes alongside a tightening of the company's full-year 2026 EBITDA guidance to $70–$80 million, down from the prior $70–$90 million range. Management cited no margin benefit from onshoring manufacturing until 2027 and prolonged higher freight costs. The company reaffirmed its Modern Oral gross sales and net sales guidance.
For investors, the CEO transition is a key event to monitor, as leadership changes can affect strategic direction. The narrowed EBITDA guidance also signals some near-term cost pressures, though the reaffirmed sales outlook provides some stability.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
The Board has appointed David E. Glazek as Chief Executive Officer effective October 1, 2026.
David Glazek, currently Executive Chairman and a director since 2012, will become CEO on October 1, 2026. He has extensive board and operating experience across CPG, media, gaming, retail, and finance.
Event · Exhibit 99.1
TPB appoints Executive Chairman David Glazek as CEO effective Oct 1, 2026, succeeding Graham Purdy, and tightens 2026 EBITDA guidance.
Added in current filing · view on EDGAR →
its Board of Directors has appointed David E. Glazek, currently Executive Chairman, as Chief Executive Officer, effective October 1, 2026. Mr. Glazek succeeds Graham Purdy, who is stepping down as Chief Executive Officer for personal reasons.
The Board appointed Executive Chairman David Glazek as CEO effective October 1, 2026. He succeeds Graham Purdy, who is stepping down for personal reasons. The filing states the departure is not related to any disagreement with the company.
Added in current filing · view on EDGAR →
The Company is reaffirming its full-year 2026 Modern Oral gross sales guidance range of $330 million to $350 million and net sales guidance of $260 million to $270 million.
TPB reaffirmed its full-year 2026 Modern Oral gross sales guidance of $330 million to $350 million and net sales guidance of $260 million to $270 million.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 22, 2026 · How we verify